Should I Sell Shire plc & Buy Omega Diagnostics Group plc Right Now?

Today you should invest in Shire plc (LON:SHP) rather than in Omega Diagnostics Group plc (LON:ODX), argues Alessandro Pasetti.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Here’s my quick take on two very different companies carrying completely different risk profiles, both operating in the pharmaceutical sector — Omega Diagnostics (LSE: ODX) and Shire (LSE: SHP).  

Omega Gets Hammered 

Omega stock took a dive in early trade today, and it is still down 18% around midday, for an implied market cap of £20m. 

That’s not something you are likely to experience with Shire, which is a much bigger and diversified pharmaceutical business, and whose shares aren’t particularly expensive right now. 

In short, Shire is an investment that deserves attention, while Omega is a speculative bet that I’d rather not consider until its development stage is completed. 

Omega’s Trading Update

The group reported today its financial results for the year ended 31 March, but something else caught investors by surprise. 

Omega said that following its last update on Visitect CD4 that confirmed “completion of the internal investigation phase” it had moved “into the process of verification and validation”.

The validation stage focused on “testing the longer-term stability of in-house manufactured finished devices“, which is a key step to production on a larger scale.

Visitect is a testing kit at a development stage that is expected to be a money-spinner.

Bad News, But Its Financials Are Ok

Unfortunately, Omega has determined that “there is a stability issue with finished product that manifests after a period of five weeks of storage at room temperature“, and this matter requires further investigation.

On 1 June, Omega’s share price rose significantly in the wake of an upbeat trading update for Visitect CD4 and other allergy developments. 

As I pointed out back then, when its shares traded at around 24p, the commercialisation of Visitect CD4 may or may not make it to the market, so Omega stock carries a huge amount of risk today, even at its current level of 18.7p a share. 

That said, it ended the year with cash reserves of £1.97m (2014: £3.12m), and a £1m undrawn credit line from its bank — enough to satisfy its funding needs for some time. 

Consider that, as it said today, it incurred in “£1.5m of capitalised development costs” during the year, “bringing the cumulative spend to date to £3.1m on the Allergy iSYS project and £1.1m on the Visitect CD4 project, neither of which has been amortised so far“.

Still, I’d look for value elsewhere. 

What Do I Like About Shire? 

Firstly, it has the backing of financial analysts, which is a good thing. The average price target from brokers stands at 5,800p, for an implied upside of 11.5% from its current level. Consensus estimates have risen 30% since July 2014. 

Secondly, its management team has delivered on its promises in recent quarters, and Shire’s projected growth rate for earnings and dividends — both at about 10% annually — are truly appealing based on forward multiples of 24x and 20x earnings in 2015 and 2016, respectively.

By comparison, Omega isn’t much cheaper. 

Finally, in the light of a market cap and an enterprise value of $48bn, Shire’s balance sheet could carry more leverage to support a more aggressive acquisition strategy or to undertake shareholder-friendly activity. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Jumbo jet preparing to take off on a runway at sunset
Investing Articles

Down 70%+ since 2020, is IAG’s share price an unmissable bargain?

IAG’s share price is still down around 73% from its pre-Covid level, but with the business performing well last year,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£17,000 of shares in the FTSE 100 dividend giant can make me £18,874 every year in passive income!

This FTSE 100 dividend superstar has an 8.8% yield with dividends projected to rise. It looks very undervalued to me…

Read more »

Investing Articles

2 top UK growth stocks I’m buying for my Stocks and Shares ISA in July

Looking for UK-listed growth firms to add to a Stocks and Shares ISA? Our writer highlights two he's planning to…

Read more »

artificial intelligence investing algorithms
Investing Articles

This overvalued growth stock makes Nvidia look cheap!

ARM Holdings is a growth stock that’s benefitted from the AI rally. Muhammad Cheema takes a look at whether this…

Read more »

Investing Articles

1 penny stock I’d buy today while it’s 63p

This penny stock's down 70% since last March, yet could be set for a big comeback as the firm rebuilds…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Buying 8,617 Legal & General shares would give me a stunning income of £1,840 a year

Legal & General shares offer one of the highest dividend yields on the entire FTSE 100. Harvey Jones wants to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

£25k to invest? Here’s how I’d try to turn that into a second income of £12,578 a year!

If Harvey Jones had a lump sum to invest today he'd go flat out buying top FTSE 100 second income…

Read more »

Union Jack flag in a castle shaped sandcastle on a beautiful beach in brilliant sunshine
Investing Articles

2 lesser-known dividend stocks to consider this summer

Summer is here and global markets could be heading for a period of subdued trading. But our writer thinks there…

Read more »